COMPARATIVE ANALYSIS OF PROSTATE SPECIFIC ANTIGEN LEVEL AND PROSTATE VOLUME WITH OVERACTIVE BLADDER IN PATIENTS WITH PROSTATE CANCER
Keywords:
Prostate cancer, prostate specific antigen, transrectal ultrasound biopsy, androgen deprivation therapyAbstract
In relation to prostate cancer prevention, the USPSTF-(UNITED STATES PREVENTIVE SERVICES TASKFORCE) task force recommends prostate-specific antigen screening for men aged 55-69 years, seeing a potential benefit in reducing mortality from this type of cancer. However, for men older than 70 years of age, the efficacy of screening appears less convincing. Prostate cancer is traditionally diagnosed by performing a finger rectal examination and prostate-specific antigen blood levels, followed by biopsy under the supervision of transrectal ultrasound. Androgen deprivation therapy alone has been shown to be associated with an increased risk of urinary incontinence compared with active surveillance. Some Asian prospective studies have reported improvement in lower urinary tract symptoms in prostate cancer patients treated with androgen deprivation therapy, with a primary focus on prostate volume reduction and improved uroflowmetry. The data of the study support the hypothesis that the introduction of complex therapy, including medication, exercise and, if necessary, androgen deprivation therapy, can significantly enhance the effectiveness of treatment of prostate cancer and overactive bladder syndrome. Not only has there been a decrease in prostate specific antigen levels and a reduction in prostate volume, but also an improvement in the overall health of patients.
In particular, the decrease in the levels of prostate specific antigen and prostate volume indicates the positive dynamics of therapy, which is especially noticeable in groups with a complex approach to treatment.
References
Kappen S, de Bock GH, Sirri E, Vohmann C, Kieschke J, Winter A. Differences in Prostate Cancer Incidence and Mortality in Lower Saxony (Germany) and Groningen Province (Netherlands): Potential Impact of Prostate-Specific Antigen Testing. Front Oncol. 2021 May 28;11:681006.
Belkahla S, Nahvi I, Biswas S, Nahvi I, Ben Amor N. Advances and development of prostate cancer, treatment, and strategies: A systemic review. Front Cell Dev Biol. 2022 Sep 9;10:991330.
Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 Apr;10(2):63-89. doi: 10.14740/wjon1191. Epub 2019 Apr 20. PMID: 31068988; PMCID: PMC6497009.
Descotes JL. Diagnosis of prostate cancer. Asian J Urol. 2019 Apr;6(2):129-136.
Sigg S, Lehner F, Keller EX, Saba K, Moch H, Sulser T, Eberli D, Mortezavi A. Outcomes of robot-assisted laparoscopic extended pelvic lymph node dissection for prostate Cancer. BMC Urol. 2024 Jan 29;24(1):24.
Baroni RH. MRI should be routine for all patients with localized prostate cancer? Opinion: Yes. Int Braz J Urol. 2016 Nov-Dec;42(6):1062-1064.
Sprute K, Kramer V, Koerber SA, Meneses M, Fernandez R, Soza-Ried C, Eiber M, Weber WA, Rauscher I, Rahbar K, Schaefers M, Watabe T, Uemura M, Naka S, Nonomura N, Hatazawa J, Schwab C, Schütz V, Hohenfellner M, Holland-Letz T, Debus J, Kratochwil C, Amaral H, Choyke PL, Haberkorn U, Sandoval C, Giesel FL. Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. J Nucl Med. 2021 Feb;62(2):208-213.
Li JR, Wang SS, Chen CS, Cheng CL, Hung SC, Lin CH, Chiu KY. Conventional androgen deprivation therapy is associated with an increased risk of cardiovascular disease in advanced prostate cancer, a nationwide population-based study. PLoS One. 2022 Jun 28;17(6):e0270292.
Akpayak IC, Shuaibu SI, Ofoha CG, Dakum NK, Ramyil VM, Onowa VE, Agbo CA, Nabasu LE, Galam ZZ. Lower urinary tract symptoms in patients with advanced prostate cancer: What are the outcomes of androgen deprivation therapy? Niger Postgrad Med J. 2020 Jan-Mar;27(1):49-53.
Alimjanovich , R. Z., Maxammatkulovich , R. N., & Khikmatovich , K. K. (2022). Age Features of the Prevalence of Prostate Cancer in Uzbekistan. Central Asian Journal of Medical and Natural Science, 3(5), 154-157. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/1062
Rizaev Jasur , Rakhimov Nodir , Kodyrov Khamidullo , Shakhanova Shakhnoza . Study of prostate cancer death by regions of the republic of Uzbekistan.Journal of Biomedicine and Practice. 2022, vol . 7, issue 5, pp.202-210
Rizaev AND . A. , Rakhimov N. M. , Kadirov X . X . RESPUBLIK A NING VILOYATL A R KESIMID A PROST A T A BEZI S A R A TONINI K A S A LL A NISH KO'RS A TGICHINI O'RG A NISH // MAGAZINE REPRODUCTIVE HEALTH AND URO - NEPHROLOGICAL RESEARCH . – 2022. – T. 3. – No. 3.
Shavkatovna, S. S., Makhammatkulovich, R. N., & Ugli, M. S. T. (2024). Aspects of sarcopenia syndrome in oncological practice: Diagnosis and treatment. The American Journal of Medical Sciences and Pharmaceutical Research, 6(2).
Shakhanova, S. S., & Rakhimov, N. M. (2025). The role of troponin and IL-6 in immunological assessment of sarcopenia in oncological patients. Central Asian Journal of Medical and Natural Science, 6(3), 1229–1233.
Rakhimov, N. M., & Shakhanova, S. Sh. (2025). Omega-3 supplementation in combination therapy for anorexia syndrome in metastatic breast cancer. American Journal of Medicine and Medical Sciences.
